Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
MYCN amplification
i
Other names:
MYCN, MYCN Proto-Oncogene BHLH Transcription Factor, V-Myc Avian Myelocytomatosis Viral Oncogene Neuroblastoma Derived Homolog, Class E Basic Helix-Loop-Helix Protein 37, N-Myc Proto-Oncogene Protein, BHLHe37, NMYC, Neuroblastoma-Derived V-Myc Avian Myelocytomatosis Viral Related Oncogene, Neuroblastoma MYC Oncogene, Oncogene NMYC, BHLHE37, MODED, N-Myc, ODED
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
4613
Related biomarkers:
Expression
Others
‹
MYCN amplification + ALK F1174V (2)
MYCN amplification + ALK rearrangement (2)
BRAF V600E + CDKN2A deletion + MYCN amplification (1)
MYCN amplification + ALK F1174L (1)
MYCN amplification + ALK R1275Q (1)
MYCN amplification + ALK F1174V (2)
MYCN amplification + ALK rearrangement (2)
BRAF V600E + CDKN2A deletion + MYCN amplification (1)
MYCN amplification + ALK F1174L (1)
MYCN amplification + ALK R1275Q (1)
›
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
MYCN amplification
Small Cell Lung Cancer
MYCN amplification
Small Cell Lung Cancer
AZD1775
Sensitive: C2 – Inclusion Criteria
AZD1775
Sensitive
:
C2
AZD1775
Sensitive: C2 – Inclusion Criteria
AZD1775
Sensitive
:
C2
MYCN amplification
Prostate Cancer
MYCN amplification
Prostate Cancer
abiraterone acetate
Resistant: C3 – Early Trials
abiraterone acetate
Resistant
:
C3
abiraterone acetate
Resistant: C3 – Early Trials
abiraterone acetate
Resistant
:
C3
MYCN amplification
Prostate Cancer
MYCN amplification
Prostate Cancer
enzalutamide
Resistant: C3 – Early Trials
enzalutamide
Resistant
:
C3
enzalutamide
Resistant: C3 – Early Trials
enzalutamide
Resistant
:
C3
MYCN amplification
Pancreatic Cancer
MYCN amplification
Pancreatic Cancer
binimetinib + encorafenib
Sensitive: C4 – Case Studies
binimetinib + encorafenib
Sensitive
:
C4
binimetinib + encorafenib
Sensitive: C4 – Case Studies
binimetinib + encorafenib
Sensitive
:
C4
MYCN amplification
Neuroblastoma
MYCN amplification
Neuroblastoma
panobinostat + GSK2816126
Sensitive: D – Preclinical
panobinostat + GSK2816126
Sensitive
:
D
panobinostat + GSK2816126
Sensitive: D – Preclinical
panobinostat + GSK2816126
Sensitive
:
D
MYCN amplification
Neuroblastoma
MYCN amplification
Neuroblastoma
OTX015
Sensitive: D – Preclinical
OTX015
Sensitive
:
D
OTX015
Sensitive: D – Preclinical
OTX015
Sensitive
:
D
MYCN amplification
Neuroblastoma
MYCN amplification
Neuroblastoma
JQ-1 + panobinostat
Sensitive: D – Preclinical
JQ-1 + panobinostat
Sensitive
:
D
JQ-1 + panobinostat
Sensitive: D – Preclinical
JQ-1 + panobinostat
Sensitive
:
D
MYCN amplification
Neuroblastoma
MYCN amplification
Neuroblastoma
brigatinib
Resistant: D – Preclinical
brigatinib
Resistant
:
D
brigatinib
Resistant: D – Preclinical
brigatinib
Resistant
:
D
MYCN amplification
Neuroblastoma
MYCN amplification
Neuroblastoma
crizotinib
Resistant: D – Preclinical
crizotinib
Resistant
:
D
crizotinib
Resistant: D – Preclinical
crizotinib
Resistant
:
D
MYCN amplification
Medulloblastoma
MYCN amplification
Medulloblastoma
sonidegib
Resistant: D – Preclinical
sonidegib
Resistant
:
D
sonidegib
Resistant: D – Preclinical
sonidegib
Resistant
:
D
MYCN amplification
Neuroblastoma
MYCN amplification
Neuroblastoma
DHODH inhibitor
Sensitive: D – Preclinical
DHODH inhibitor
Sensitive
:
D
DHODH inhibitor
Sensitive: D – Preclinical
DHODH inhibitor
Sensitive
:
D
MYCN amplification
Neuroblastoma
MYCN amplification
Neuroblastoma
olaparib + MK-8776
Sensitive: D – Preclinical
olaparib + MK-8776
Sensitive
:
D
olaparib + MK-8776
Sensitive: D – Preclinical
olaparib + MK-8776
Sensitive
:
D
MYCN amplification
Medulloblastoma
MYCN amplification
Medulloblastoma
olaparib + MK-8776
Sensitive: D – Preclinical
olaparib + MK-8776
Sensitive
:
D
olaparib + MK-8776
Sensitive: D – Preclinical
olaparib + MK-8776
Sensitive
:
D
MYCN amplification
Neuroblastoma
MYCN amplification
Neuroblastoma
venetoclax + LY3295668
Sensitive: D – Preclinical
venetoclax + LY3295668
Sensitive
:
D
venetoclax + LY3295668
Sensitive: D – Preclinical
venetoclax + LY3295668
Sensitive
:
D
MYCN amplification
Neuroblastoma
MYCN amplification
Neuroblastoma
KB-0742
Sensitive: D – Preclinical
KB-0742
Sensitive
:
D
KB-0742
Sensitive: D – Preclinical
KB-0742
Sensitive
:
D
MYCN amplification
Rhabdomyosarcoma
MYCN amplification
Rhabdomyosarcoma
selinexor + VIP152
Sensitive: D – Preclinical
selinexor + VIP152
Sensitive
:
D
selinexor + VIP152
Sensitive: D – Preclinical
selinexor + VIP152
Sensitive
:
D
MYCN amplification
Rhabdomyosarcoma
MYCN amplification
Rhabdomyosarcoma
bortezomib + VIP152
Sensitive: D – Preclinical
bortezomib + VIP152
Sensitive
:
D
bortezomib + VIP152
Sensitive: D – Preclinical
bortezomib + VIP152
Sensitive
:
D
MYCN amplification
Rhabdomyosarcoma
MYCN amplification
Rhabdomyosarcoma
VIP152
Sensitive: D – Preclinical
VIP152
Sensitive
:
D
VIP152
Sensitive: D – Preclinical
VIP152
Sensitive
:
D
MYCN amplification
Neuroblastoma
MYCN amplification
Neuroblastoma
VIP152
Sensitive: D – Preclinical
VIP152
Sensitive
:
D
VIP152
Sensitive: D – Preclinical
VIP152
Sensitive
:
D
MYCN amplification
Rhabdomyosarcoma
MYCN amplification
Rhabdomyosarcoma
carfilzomib + VIP152
Sensitive: D – Preclinical
carfilzomib + VIP152
Sensitive
:
D
carfilzomib + VIP152
Sensitive: D – Preclinical
carfilzomib + VIP152
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login